DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/11e326/genzyme_corporatio) has announced the addition of the "Genzyme Corporation: PharmaVitae Profile" company profile to their offering.
This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
- See how the company's core products of Cerezyme, Fabrazyme and Myozyme/Lumizyme will continue to act as the primary sales growth drivers
- Assess the impact of the recent contamination of the Allston manufacturing facility on the company's performance through 2009
Key Topics Covered:
Chapter 1 About this profile
Chapter 2 Executive summary
Chapter 3 Quarterly news update
Chapter 4 Company introduction
Chapter 5 Company sales
Chapter 6 Company financials
Chapter 7 Key products and competitors
Chapter 8 Appendix
- Amgen Inc.
- AstraZeneca PLC
- Chugai Pharmaceutical Co. Ltd
- Genentech, Inc.
- Genzyme Corporation
- Gilead Sciences, Inc.
- IMS Health
For more information visit http://www.researchandmarkets.com/research/11e326/genzyme_corporatio
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: United States North America
INDUSTRY KEYWORDS: Health Pharmaceutical